Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354271 | 0.91 | ACHE (0.52) | EPHX2ACHEPTGIRMAPTKDM4E | |
| SCHEMBL6347280 | 0.90 | MAPT (0.48) | ALDH1A1EPHX2ACHEPTGIRMAPT | |
| SCHEMBL6346963 | 0.90 | ACHE (0.52) | EPHX2ACHEPTGIRMAPTKDM4E | |
| SCHEMBL6346311 | 0.87 | ACHE (0.51) | EPHX2ACHEHTTPTGIRMAPT | |
| Trifluoroacetic Acid SCHEMBL6354143 | 0.85 | ACHE (0.46) | ALDH1A1EPHX2ACHEPTGIRMAPT | |
| SCHEMBL6344309 | 0.85 | ACHE (0.48) | ALDH1A1EPHX2ACHEPTGIRMAPT | |
| SCHEMBL6347249 | 0.85 | ACHE (0.47) | ALDH1A1EPHX2ACHEPTGIRMAPT | |
| SCHEMBL6346829 | 0.84 | SIGLEC9 (0.51) | ALDH1A1EPHX2ACHEDRD2DRD3 | |
| SCHEMBL6354903 | 0.84 | ACHE (0.48) | ALDH1A1EPHX2ACHEHTTPTGIR | |
| SCHEMBL6344302 | 0.84 | EPHX2 (0.43) | ALDH1A1EPHX2HTTMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
| EP-1289950-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-1192135-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192132-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001096296-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000076970-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000076971-A2 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | ALDH1A1 3720/4885EPHX2 1259/4885ACHE 1821/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | ALDH1A1 2527/4885EPHX2 777/4885ACHE 1271/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ALDH1A1 2261/4885EPHX2 1576/4885ACHE 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.